Cadrenal CEO sells 8,285 shares under 10b5-1 plan

Cadrenal Therapeutics, Inc. CEO and Chairman Quang X. Pham reported open-market sales of a total of 8,285 shares of common stock on June 3–5, 2026 at weighted average prices of $4.26, $4.41 and $4.42 per share.

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. CEO and Chairman Quang X. Pham reported open-market sales of a total of 8,285 shares of common stock on June 3–5, 2026 at weighted average prices of $4.26, $4.41 and $4.42 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the transactions, he holds 173,224 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.

Insider Trade Summary 10b5-1

Net Seller: 8,285 shares

Net Sell 4 txns

Insider Pham Quang X

Role CEO and Chairman

Sold 8,285 shs ($36K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,064	$4.42	$9K
Sale	Common Stock	3,898	$4.41	$17K
Sale	Common Stock	2,323	$4.26	$10K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 173,224 shares (Direct); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)

Footnotes (5)

1. F1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 through $4.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 through $4.47. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.25 through $4.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

Key Figures

Shares sold June 3, 2026: 2,323 shares at $4.26 Shares sold June 4, 2026: 3,898 shares at $4.41 Shares sold June 5, 2026: 2,064 shares at $4.42 +4 more

7 metrics

Shares sold June 3, 2026 2,323 shares at $4.26 Open-market sale of common stock by CEO

Shares sold June 4, 2026 3,898 shares at $4.41 Open-market sale of common stock by CEO

Shares sold June 5, 2026 2,064 shares at $4.42 Open-market sale of common stock by CEO

Total shares sold 8,285 shares Net open-market sales across June 3–5, 2026

Direct holdings after trades 173,224 shares Common stock directly owned by CEO post-transaction

Indirect trust holdings 200,000 shares Common stock held via The PVBQ Living Trust

Rule 10b5-1 plan adoption date September 25, 2025 Date CEO adopted trading arrangement governing these sales

Key Terms

Rule 10b5-1 trading arrangement, weighted average price, The PVBQ Living Trust, voting and dispositive power

4 terms

Rule 10b5-1 trading arrangement regulatory

"sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

The PVBQ Living Trust financial

"Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting"

voting and dispositive power regulatory

"has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Cadrenal Therapeutics (CVKD) disclose on this Form 4?

Cadrenal Therapeutics disclosed that CEO and Chairman Quang X. Pham sold 8,285 shares of common stock in open-market transactions between June 3 and June 5, 2026 at weighted average prices around $4.26 to $4.42 per share, under a pre-arranged Rule 10b5-1 plan.

At what prices did the Cadrenal Therapeutics (CVKD) CEO sell shares?

The CEO’s reported weighted average sale prices were $4.26, $4.41 and $4.42 per share. Footnotes explain that each reported price reflects multiple trades within specified intraday ranges, and full transaction-by-price details are available on request from the company, shareholders, or the SEC staff.

How many Cadrenal Therapeutics (CVKD) shares does the CEO still own after these sales?

After the reported sales, Quang X. Pham directly owns 173,224 shares of Cadrenal Therapeutics common stock and indirectly holds 200,000 additional shares through The PVBQ Living Trust, giving him sole voting and dispositive power over the trust’s position according to the filing footnotes.

Were the Cadrenal Therapeutics (CVKD) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the common stock sales were made under a Rule 10b5-1 trading arrangement adopted by Quang X. Pham on September 25, 2025. Such pre-arranged plans allow insiders to schedule trades in advance, separating trading decisions from day-to-day market developments.

What role does The PVBQ Living Trust play in Cadrenal Therapeutics (CVKD) insider ownership?

The PVBQ Living Trust holds 200,000 Cadrenal Therapeutics shares as an indirect position for Quang X. Pham. He serves as trustee with sole voting and dispositive power, while his child is the trust’s sole beneficiary, according to the detailed ownership footnote in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FLORIDA 32082

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		S		2,323(1)	D	$4.26(2)	179,186	D
Common Stock	06/04/2026		S		3,898(1)	D	$4.41(3)	175,288	D
Common Stock	06/05/2026		S		2,064(1)	D	$4.42(4)	173,224	D
Common Stock								200,000	I	The PVBQ Living Trust(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 through $4.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 through $4.47. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.25 through $4.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Quang X. Pham	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)